Review

Review on the update in obesity management: epidemiology

Abstract

Obesity remains one of the largest public health issues in the developed world. Over the past 50 years, the prevalence of this disease has risen to epidemic proportions and remains on the rise. Importantly, the incidence of obesity coincides with an increased risk of cardiovascular disease, type II diabetes, hypertension, fatty liver disease, obstructive sleep apnoea and several cancers. This article is the first of a three-part series of reviews surveying the obesity epidemic and interventions to address it. It provides an overview of the disease’s prevalence, aetiology and comorbidities as well as the guidelines currently available to treat obesity. Obesity is a multifactorial disease with a complex aetiology. Genetic, environmental and epigenetic factors contribute to the occurrence of obesity. Examples include the thrifty gene hypothesis, epigenetics and the presence of obesogenic environments. Furthermore, an imbalance in energy intake versus expenditure encourages weight gain. Current guidelines aim to instruct primary care practitioners on the appropriate diagnostic and therapeutic tools to use in patients with obesity. Obesity remains an important public health concern with many causes, influences and outcomes for patients.

Definition of obesity

Obesity is defined as the excess accumulation of adipose tissue in the body leading to health complications and impairment in normal functioning.1 The most commonly used tool in clinics to diagnose obesity is body mass index (BMI).2 BMI is calculated as weight in kilograms divided by height in metres squared (m2).2 The Center for Disease Control classifies weight status according to BMI ranges: underweight is <18.5 kg/m2; normal weight is a BMI of 18.5–24.9 kg/m²; overweight is 25.0–29.9 kg/m2 and obese is >30 kg/m².3 In addition, obesity is further separated into three classes, with class I being 30.0–34.9 kg/m², class II being 35.0–39.9 kg/m² and class III being >40 kg/m2.4

Prevalence of obesity

Overweight and obesity are considered a global health issue.5 The WHO estimates that in 2022, 59% of adults are living with overweight or obesity and approximately half of the population in 50 out of 53 European countries part of the WHO are overweight or obese.6 Regardless of ethnicity, sex, socioeconomic status or geographic location, obesity rates have increased in all age groups across the globe.7 According to WHO, the prevalence of overweight and obesity ranges from less than 20% in some countries to greater than 60% in some countries. The countries with the highest prevalence of obesity were high-income countries in North and South America, Europe and Oceania8 (figure 1). The countries with the lowest prevalence of obesity are predominantly in sub-Saharan Africa and Southeast Asia.8 The variation between high and low-prevalence countries is steep. Japan’s obesity prevalence is 3.7% while the USA has a prevalence of 38.2%.8 Having a large population base also affects obesity epidemiology. China and India both have a large number of individuals with obesity, but due to their large populations, only report a prevalence of 5.7% and 5%, respectively.8 In addition, the rise and fall of this disease can vary within individual countries. Over the past 20 years, trends in obesity have been steadily increasing.9 In the 1980s, approximately 3% of men and 6% of women globally were obese compared with 16% of women and 12% of men in 20209 (figure 2). In the USA, obesity prevalence rose from 30.5% in 1999–2000 to 41.9% in 2017–2020.10 The prevalence of severe obesity, defined as having a BMI of >40 kg/m2, rose from 4.7% to 9.2%.10 Legislative approaches, such as taxing junk food, improving nutritional labelling and definitions of serving sizes, banning certain ingredients and regulating sodium consumption have been instituted to mitigate the obesity pandemic.11 However, wide gaps in evidence-to-practice prevent the optimal functioning of these regulations.

Figure 1
Figure 1

Prevalence of obesity among adults, body mass index (BMI) >30 (age-standardised estimate) (%). Reproduced with permission from the WHO, 2021.

Figure 2
Figure 2

The age-standardised global prevalence of obesity in men and women >20 years old by year. Reproduced with permission from Boutari and Mantzoros.9

Causes of obesity

Obesity is a multifactorial disease with a complex aetiology.12 A simple balance between food intake, metabolism and energy expenditure is the main mechanism responsible for weight maintenance and weight gain.13 However, this balance is very much influenced by environmental factors as well as an individual’s genetic makeup.13 A full review of the causes of obesity is beyond the scope of this paper. However, it is important to note that the complex nature of this disease means that it is not easily treated in clinics and is a significant global public health problem. Understanding the intricate links between environmental and genetic causes of obesity and clinical challenges in managing this disease, sheds light on its complex nature, emphasising the need for holistic strategies that address both lifestyle and systemic factors in combating obesity.

Genetic causes

Studies have shown that obesity has a heritability of 40%–70%, demonstrating that there is a large genetic component to this disease.14 Obesity can be monogenetic, polygenetic or syndromic. Monogenic obesity is caused by mutations in a single gene. Most often, these mutations occur in genes that are part of the leptin-melanocortin pathway.15 Examples of genes involved in monogenetic obesity include leptin and leptin receptor (LEP and LEPR), pro-opio melanocortin (POMC) and melanocortin (MCR4) receptor.15 Polygenetic obesity is caused by mutations in multiple genes whose effects are amplified by ‘obesity-promoting’ or obesogenic environments.16 Syndromic obesity is associated with other phenotypes such as neurodevelopmental abnormalities and organ malformation.17 An example of syndromic obesity is observed in the rare cases of Bardet Biedl syndrome (BBS) and Prader-Willi syndrome (PWS).15 BBS is an autosomal recessive genetic ciliopathic syndrome affecting many body organs and causing intellectual disability, obesity, hypogonadism, genitourinary and urinary abnormalities, and polydactyly.18 PWS is the most common cause of syndromic obesity and is characterised by specific facial features, neonatal hypotonia, failure to thrive, hypogonadism, early childhood onset obesity, hyperplasia, developmental delay/mild intellectual ability and short stature.19

Obesogenic environments

The increase in obesity may be linked to the presence of an obesogenic environment, particularly in the context of a genetic predisposition to obesity. Researchers have suggested that obesogenic environments are an important cause of obesity in North America.20 The built environment, which encompasses a person’s surroundings and infrastructure, can affect an individual’s risk of developing obesity through behaviour modification and direct exposure.21 Environmental factors such as urbanisation, greenspace, walkability and exposure to air pollution can influence changes in a person’s weight.22 A 2021 umbrella review evaluating the associations between the built environment and obesity revealed that more exposure to fast-food, and increased urban sprawl were associated with increases in obesity.22 The flipping point from non-obesogenic to obesogenic environments in North America occurred in the early 1970s.13 At this time, carbohydrate and fat-rich foods became predominant and technological innovation reduced human energy expenditure.23 Coupled together, these changes resulted at the beginning of the obesity pandemic. Before 1960, decreased energy expenditure was matched by a decrease in energy intake, resulting in a stable level of obesity in the North American population13 (figure 3). From 1970 onwards, this balance was disrupted as energy intake began to increase and energy expenditure began to decrease.13

Figure 3
Figure 3

Amount of individual energy expenditure (blue) and individual energy intake (red) from 1910 to 2000. Stable weight phase is indicated in green, energy flipping point in red and weight-gain phase in blue. Reproduced with permission from Blüher.13

Thrifty gene hypothesis

The thrifty gene hypothesis has also been explored as a possible cause for the current rise in overweight and obesity. According to this hypothesis, our ancestors underwent positive selection for genes with energy-conserving or fat-depositing functions since they increased an individual’s odds of survival during periods of famine.24 In modern obesogenic environments, these genes cause people to be overweight or obese. A comparison of the average body measurements for women in the 1960s versus the 2020s accurately displays this notion. In 1960, the average woman weighed 141 lbs or 64 kg and her height was 5′2″ or 160 cm.25 Consequently, her BMI was 25. In 2021, the average North American woman weighs 170.8 lbs or 77.5 kg and her height is 5′3″ or 161 cm, making her BMI 30.0.26 This classifies her as obese and puts her at an increased risk of cardiometabolic disease and mortality.

Several studies have been conducted to determine whether the thrifty gene hypothesis can be supported. To date, no specific genes or molecular mechanisms have been directly associated with this phenomenon.27 However, it is clear that the ‘thrifty phenotype’ is present in societies.28 Past evidence suggests that the body’s leptin resistance level and epigenetic modifications could be responsible for some ‘thrifty phenotypes’.29 Other potential players include genes responsible for encoding the insulin signalling and intermediary fat metabolism.30 Recently, the Peroxisome proliferator-activated receptor γ coactivator-1α gene has been identified as a potential contributor to high BMI in certain populations.31 Further investigation is required to validate this hypothesis.

Epigenetics

Epigenetics involves the study of heritable changes in gene expression.32 These changes are dynamic. Therefore, factors such as exposure to obesogenic environments can alter the epigenetic makeup of an individual’s DNA and can subsequently influence the phenotypic expression of obesity. Important epigenetic mechanisms in obesity include DNA methylation, histone modification and microRNA (miRNA) regulation.33

DNA methylation involves the transcriptional regulation of expression of certain genes by adding a methyl group to a cytosine base pair adjacent to a guanine base pair (also called CpG islands) in the DNA sequence.34 These cytosines are often located in promoter regions of genes and therefore affect their expression.35 DNA hypermethylation is associated with an inhibition of gene expression while hypomethylation causes activation of gene expression.36 Methylation changes in genes associated with appetite, growth, metabolism, insulin signalling and obesity-related phenotypes are potentially involved in the phenotypic expression of obesity.35 The LEP and POMC genes, both involved in weight regulation, have CpG islands in their genetic code.37 Elevated LEP methylation in maternal blood samples has been associated with pre-pregnancy obesity and subsequent infant blood LEB methylation.38 POMC methylation has been associated with metabolic syndrome and is an early indicator of such diseases.39 Other methylated genes of interest include the hypoxia-inducible factor 3a, adiponectin, peroxisome proliferator-activated receptor coactivator 1 α, insulin-like growth factor 2, insulin receptor substrate 1 and lymphocyte antigen 86.40

Histone modifications occur when proteins called histones bind to exposed DNA, thereby inhibiting further modification, such as DNA methylation or acetylation that could alter gene expression.41 This mechanism plays an important role in adipogenesis and obesity development through the modulation of key regulatory genes.42 These genes are preadipocyte factor-1 (Pref-1), CCAAT-enhancer-binding protein β (C/EBP β), C/EBPα, PPARγ and adipocyte protein 2 (aP2). During adipocyte differentiation, the Pref-1 gene is less active and the C/EBP β gene has increased active chromatin markers. On induction, C/EBPα significantly loses its repressive methylation and the PPARγ and the aP2 gene are significantly expressed during adipogenesis. Furthermore, differential expression of histone deacetylases is observed in the hypothalamus of fasting, fed and high-fat diet animals.43 Importantly, environmental changes have an impact on chromatin remodelling through histone modification. Alterations in diet have been shown to remodel chromatin, thus affecting the expression of liver transcription factors, nuclear factors and enhancer binder proteins.44 Other studies have shown that the POMC gene which regulates appetite undergoes histone acetylation in addition to DNA methylation.45 Therefore, it is possible that multiple epigenetic modification work in concert to regulate the phenotypic expression of obesity.

miRNA are short non-coding strands of RNA that regulate or silence gene expression.46 They bind to complementary mRNA sequences and cause degradation or inhibit protein translation. MiRNAs have been known to regulate metabolic processes.47 Their dysregulation has been associated with obesity.48 This regulatory mechanism modulates paracrine signalling between adipose tissue, skeletal muscles, the liver and other organs which can influence energy homeostasis and metabolism.49 Importantly, many miRNAs in the body can be found in adipose tissues and can regulate adipocyte proliferation, insulin resistance differentiation and inflammation.43 Previous studies have identified miR-328, miR-378, miR-30b/c, miR-455, miR-32 and miR-193b-365 as activators of brown adipogenesis while miR-34a, miR-133, miR-155 and miR-27b appear to inhibit this mechanism.50 During obesity, the miRNA population can be significantly altered in adipose tissue, further influencing the development of obesity and some forms of cancer.51 Further research is required to understand the full extent of miRNA’s impact on obesity phenotypes.

Exposure to obesogenic environments can alter epigenetics and influence obesity. Previous studies have linked exposure to phthalates, pesticides and bisphenol A to increased levels of obesity.45 These chemicals can act as endocrine disruptors and affect the regulation of obesity-related pathways in the body. Diet has also been linked to changes in epigenetics. Malnutrition of infants during the Dutch famine has been linked to obesity, hypertension and diabetes in later life.52 Endurance training and increased physical activity have also been shown to alter DNA methylation in 63 genes related to obesity.53 Exercise can reverse the epigenetic effects of a sedentary lifestyle that can contribute to obesity. Furthermore, reduced levels of sleep and alcohol consumption also have epigenetic effects on obesity. In all, epigenetics plays an important role in causing obesity.

Composition of gut microbiota

Gut microbiota, mainly located in the large colon, are involved in metabolism regulation, nutrient absorption, synthesis of vitamins, regulation of gene expression and food digestion.54 Several studies conducted in lean and obese mice have concluded that differences in the gut microbiome can contribute to the development of obesity and might be an essential player in energy regulation.55 Obese mice had 50% fewer Bacteroidetes and an increased amount of Firmicutes, two phyla that dominate the gut microbiome.56 Further animal and human studies have reached similar conclusions.57 Firmicutes can produce short-chain fatty acids (SCFAs) from non-digestible dietary starches.54 SCFAs can promote obesity by providing an increased caloric intake, increasing fat deposition in the body and acting on energy and metabolism pathways.58 Diet can also induce changes in gut microbiota.54 High-fat diets have been associated with increased gut permeability which causes gut inflammation and metabolic disturbances associated with obesity.59 High-fibre diets are beneficial in promoting weight loss, despite the diets not being calorie restrictive.60 Other factors such as physical activity level, stress, breastfeeding, mode of childbirth, sleep disturbances and antibiotic use are also associated with changes in the gut microbiome.54 To date, analysing the gut microbiome of patients with obesity does not confer any diagnostic knowledge nor does it provide indications as to which treatments will benefit the patient.61 More research is required to determine the exact profile of gut microbiota in obese individuals, should it exist and how this information can help optimise weight loss. Some studies have shown that in patients with obesity and metabolic disorders compared with patients with obesity without metabolic disorders have different gut microbiota profiles.62–64 However, confounders such as differing diets, environments and genetic factors are present in these studies. Further research assessing the impact of these factors on the gut microbiome must be conducted to increase the value of the gut microbiome in the treatment of obesity.

Consumption of subsidised crops leads to obesity

Studies have identified that the consumption of foods from subsidised crops is linked to an increased cardiometabolic risk.65 Agricultural subsidies primarily support the production of corn, soybeans, wheat, rice, sorghum, dairy and livestock feed.65 These crops are further processed and become calorie-dense foods such as high fructose corn syrup, cereals and alcohol.66 Populations that consume a high number of subsided foods are 49% more likely to be obese and 61% more likely to have a higher abdominal adiposity score than people who consume low amounts of subsided crops (figure 4). In addition, the prevalence of dysglycaemia also increased across these populations. This link is evidence that the consumption of subsidised crops is associated with a higher risk of cardiometabolic disorder.

Figure 4
Figure 4

Adjusted prevalence of obesity (A), abdominal adiposity (B) and dysglycaemia (C) by subsidy score quartile in the National Health and Nutrition Examination Survey between 2001–2006 and 2009–2014. Subsidy score quartiles were defined as follows: Q1 is 0.00–0.41; Q2 is 0.42–0.53; Q3 is 0.54–0.63; and Q4 is 0.64–1.00. Obesity was defined as a body mass index of at least 30 kg/m2. Abdominal adiposity was defined as a ratio of waist circumference to height of at least 0.59. Dysglycaemia was defined as a self-reported diabetes diagnosis or haemoglobin A1c level of at least 5.7%. Reproduced with permission from Do et al.65

Calorie imbalance: intake versus expenditure

It is common for individuals to underestimate their daily caloric intake and overestimate the number of calories they burn during physical activity. The imbalance of calorie intake and energy expenditure most individuals experience is the main reason obesity is such a common and difficult disease to manage. A typical 50-year-old man who measures 5′8″, weighs 200 lbs and has a BMI of 30.4 requires 2090 calories per day to maintain their weight, assuming they have a sedentary lifestyle.67 To lose one pound per week, this individual would have to consume 75% of their daily requirements (1590 cal/day).68 To lose two pounds per week or approximately 1 kg, the individual would have to reduce their intake by almost 50% (1090 cal/day). This is a significant reduction from this individual’s original daily calorie intake. Therefore, individuals may be unaware how much of a reduction in calories are required to achieve a small weight change. An average 50-year-old woman measuring 5′3″, weighing 178 pounds with a BMI of 30 and a sedentary lifestyle requires less caloric intake to maintain her weight.67 She needs to consume 1676 cal/day to maintain her weight while a male requires 2090 cal/day.68 To lose one pound a week, this individual has to reduce her calorie intake by 30% to 1176 cal/day. She would have to reduce her intake by 60% to 676 cal/day to lose two pounds a week.

Not only do individuals overestimate their daily calorie requirement, but they also underestimate the number of calories their food contains and the amount of physical activity required to burn off these calories. For instance, a big Mac Trio, which includes a Big Mac hamburger, medium fries and a large soft drink, contains 1100 calories. This is 59% of the daily caloric requirements for an average 50-year-old man and 74% of the daily caloric intake for a 50-year-old woman.69 The amount of exercise required to expend 1000 calories is significant. Examples include running vigorously for 70 min, walking for 5 hours at a brisk pace or cycling at 14 mph for 70 min.70 The disparity between calorie intake and energy expenditure makes obesity a particularly challenging condition to address.

Comorbidities associated with obesity

Obesity has been associated with many comorbidities including type II diabetes, dyslipidaemia, cancer, mood disorders, heart disease, reproductive disorders, liver disease and hypertension among others.5 Figure 5 illustrates the BMI cut-offs after which the prevalence of the listed comorbidities increases.71 Coronary artery disease prevalence increases above a BMI of 27.7, hyperlipidaemia increases substantially above a BMI of 27.1, hypertension above a BMI of 28.4, obstructive sleep apnoea above a BMI of 30.1, osteoarthritis increases above a BMI of 28.7 and diabetes mellitus increases substantially above a BMI of 30.9.71 A fivefold and fourfold increase in the incidence of both osteoarthritis and diabetes mellitus respectively occurs once an individual becomes obese.71 The association between BMI and comorbidity incidence is more reason to ensure that obesity in clinics is being effectively managed through comprehensive and multifaceted approaches.

Figure 5
Figure 5

Cut points and comorbidity incidence. Grey shaded areas represent 95% CIs. The dotted line and the values in the box represent BMI cut points. ‘Below’ corresponds to overall disease incidence (per 100 person-years) for all patients with a BMI that is less than the cut point. ‘Above’ corresponds to overall disease incidence (per 100 person-years) for all patients with a BMI that is greater than the cut point. Reproduced with permission from Liu et al.71 BMI, body mass index; OSA, obstructive sleep apnoea.

Weight loss has been associated with an improvement in comorbidities as well as cardiovascular risk factors. Several studies have examined the impact of weight loss on morbidity and mortality in obese patients. In patients who undergo bariatric surgery, 90.2% remitted their sleep apnoea, 80.7% remitted their diabetes and 70.8% remitted their hypertension when followed up at 41 months.72 In 93% of cases, patients evaluated their quality of life postoperation as positive and 94% indicated their quality of life improved greatly postoperation. Barrett’s oesophagus and gastric reflux disease were also significantly reduced in patients who received sleeve gastrectomy (73.7%).73 The Look AHEAD Trial reported that in patients who lost >10% of their body weight, their risk for composite cardiovascular disease death, myocardial infarction, stroke or angina hospitalisation was reduced by 21%, their risk for coronary artery bypass grafting, carotid endarterectomy, percutaneous coronary intervention, hospitalisation for congestive heart failure, peripheral vascular disease and mortality decreased by 24%.74 Importantly, patients who increased their physical activity also reduced their risk of cardiovascular intervention and hospitalisation due to heart failure in the Look AHEAD Trial. Therefore, losing weight can significantly improve the overall health of obese patients.

Obesity guidelines

Guidelines have been issued for obesity management by several organisations. In particular, the ‘European practical and patient-centred guidelines for adult obesity management in primary care’, the ‘Obesity in adults: practical clinical practice guideline’ from the Canadian Medical Association and the National Institutes of Health’s ‘The practical guide identification, evaluation, and treatment of overweight and obesity in adults’.75–77 These guidelines suggest simple interventions for physicians to use when assessing and treating overweight and obesity. The American College of Cardiology and American Heart Association has not released new guidelines since 2013.78 Current guidelines suggest three steps to implement in the interaction between physicians and patients.

The first step is to recognise the condition. During this step, the physician should ask the patient for permission to discuss their weight. Asking permission shows compassion and empathy and builds patient-provider trust.

Step 2 is the assessment of the patient’s medical history. This step helps physicians assess the patient’s medical history, lifestyle, behaviours and goals to create an individualised and effective weight loss strategy. The Edmonton Obesity Staging System (EOSS) is a suggested tool to use to assess the patient’s risk factors for developing obesity and weight-related comorbidities.79 The EOSS is comprised five stages, each assessing a patient’s medical, mental and functional risk factors for developing weight-related comorbidities, beyond their weight. Stage 0 indicates that the patient demonstrates no clinical risk factors while stage 4 indicates that the patient demonstrates severe clinical risk factors for weight-related problems. While clinical guidelines suggest that BMI is a valuable screening tool for obesity, they also acknowledge its limitations. One limitation of BMI is that it does not take into account body composition.80 BMI determines weight classification based on a patient’s height but does not distinguish between lean body mass (LBM) and adipose tissue.80 Excess levels of adipose tissue have been associated with detrimental health outcomes whereas LBM, which includes skeletal muscle, may provide some benefits.80 Therefore, measuring the amount of LBM versus adipose tissue in obese patients could be useful to determine potential health outcomes and treatments.80 To date, there are limited ways for physicians to quickly determine LBM in large patient populations. BMI and waist circumference remain the best ways to determine obesity despite their limitations.

Waist circumference is a good representation of the amount of visceral fat in an individual’s abdomen.77 Together, the EOSS, BMI and waist circumference can provide a clear idea of a patient’s risk of obesity and weight-related complications.

The final step includes treating the patient’s condition.77 Particularly, physicians should advise the patient on how to manage their weight. Therapies include nutrition therapy such as personalised counselling by a registered dietitian, focusing on healthy food choices and evidence-based nutrition therapy. 30–60 min of moderate to vigorous physical activity on most days is recommended for overweight and obese patients.81 In addition to nutrition and exercise, step 3 also involves an assessment of psychological counselling, pharmacotherapy and bariatric surgery.77 For psychological interventions, they suggest a cognitive approach to behaviour change, including managing sleep, time and stress, and additional psychotherapy if appropriate. The guidelines suggest that in some situations, antiobesity medications may be useful for weight loss and maintenance of weight loss. Finally, bariatric surgery is an appropriate intervention for severely obese patients and should be discussed between the patient and the bariatric surgeon.

Guidelines suggest that at each annual check-up, a patient’s weight, height, waist circumference and BMI be measured.77 If a patient is overweight, meaning they have a BMI between 25 and 29.9 kg/m², they should be assessed for cardiovascular disease and their weight and BMI should be assessed annually. If the patient is obese, meaning they have a BMI >30 kg/m², they should be asked about their willingness to lose weight. Intensive lifestyle changes should be suggested if they are willing to lose weight. Pharmacotherapy should be explored as an immediate treatment option if the patient has a BMI of >30 kg/m² or 27 kg/m² and one weight-related comorbidity. Patients who have a BMI>40 kg/m² or a BMI of >35 kg/m² and at least one weight-related comorbidity are eligible for a bariatric surgery consultation. Finally, if the patient is not meeting their weight loss goals after 3 months, intensive behavioural counselling and reevaluation should take place.

Review | 27 November 2024
Review on obesity management: bariatric surgery

Katya Peri, Mark Eisenberg

Review | 27 November 2024
Review on obesity management: diet, exercise and pharmacotherapy

Katya Peri, Mark Eisenberg